Home
    • Plans Blog Contact
    Protagenic Therapeutics logo

    Protagenic Therapeutics

    PTIX
    Last price US$0.321
    Market cap US$1.3m
    12M price change N/A
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Syneos HealthSYNH Industry peer Pluri IncPLUR Industry peer Prenetics Global LtdPRE Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Protagenic Therapeutics Overview

    Industry: Biotechnology & Medical Research

    Sector: Healthcare

    Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York. Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signal Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Protagenic Therapeutics into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 14, 2026

    Quarterly result summary

    Latest company-filed earnings material is available for source review.

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    SEC filing Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Mar 09, 2026 SEC filing 10-Q Nov 26, 2025 SEC filing 10-Q May 13, 2025 SEC filing 10-K filing Mar 31, 2025 SEC filing 10-Q filing Nov 14, 2024 SEC filing 10-Q filing Aug 14, 2024 SEC filing 10-Q filing May 15, 2024 SEC filing 10-K/A filing May 14, 2024

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Protagenic Therapeutics earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology & Medical Research industry , Syneos Health , Pluri Inc , Prenetics Global Ltd are companies with high ratings.

    Return on Equity

    Score -0.12/5
    Protagenic Therapeutics exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Protagenic T... PTIX US$1.3m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Protagenic Therapeutics olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Protagenic T... PTIX US$1.3m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology & Medical Research industry , Syneos Health , Pluri Inc , Prenetics Global Ltd are companies with high ratings.

    Leverage

    Score 3.57/5
    Protagenic Therapeutics attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Protagenic T... PTIX US$1.3m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Protagenic Therapeutics logo

    Protagenic Therapeutics

    US$0.321

    US$1.3m

    3.42%

    N/A